No Benefit in Outcomes With Higher Resource Use in Metastatic Prostate Cancer
Increases in monitoring of prostate-specific antigen (PSA) levels and bone health were not associated with improved survival or quality of... Read More
‘Screening Smarter’ for Prostate Cancer
Screening for prostate cancer with the prostate-specific antigen (PSA) test, once widely promoted for all men 50 years and older,... Read More
Immunotherapy for Prostate Cancer: Where Do We Go From Here?
Immunotherapies have emerged as a revolutionary modality for cancer treatment, and a variety of immune-based approaches are currently being investigated... Read More
Early ADT for Incurable Prostate Cancer Has Limited Impact on QOL
Immediate treatment with androgen-deprivation therapy (ADT) for men with asymptomatic non-curable prostate cancer did not have major effects on quality... Read More
Prostate Cancer Patients Can Improve Bone Health With Osteoporosis Medications
Men with non-metastatic prostate cancer who receive androgen deprivation therapy (ADT) risk loss of bone mineral density (BMD) and fractures,... Read More
New ASCO Guideline on Second-Line Hormone Therapy in Prostate Cancer
The American Society of Clinical Oncology (ASCO) issued the first guidance, a provisional clinical opinion (PCO), on second-line hormonal therapy... Read More
Current Guidelines Miss Relevant Germline Mutations in Prostate Cancer
National Comprehensive Cancer Network (NCCN) genetic testing guidelines and Gleason scores do not predict which patients with prostate cancer will... Read More
Marker in Prostate Cancer Fails to Predict Response to PARP Inhibition
Maha H. Hussain, MD, of the Lurie Cancer Center in Chicago, discusses clinical and genomics data from the NCI 9012... Read More
‘High-Intensity’ Sequencing Detected Breast, Prostate Cancers in Blood
A novel high-intensity sequencing approach enabled broad detection of genomic variants in plasma with high rates of concordance with corresponding... Read More
Reducing ADT to 18 Months May Be Sufficient in High-Risk Prostate Cancer
Androgen deprivation therapy (ADT) can be safely reduced from 36 months to 18 months in high-risk prostate cancer, according to... Read More